Transcenta has established a pipeline of over ten innovative molecules in oncology, bone disorders and nephrology. Most of these are discovered and developed in house and some are acquired through in-licensing.
Program Target Indication |
Pre-clinical IND Filing Ph I Ph II Ph III NDA/BLA Filing |
Territory |
MSB2311 PD-L1 Solid Tumors |
![]() ![]() MSB2311 - PD-L1 - Solid Tumors
Territory:Global |
Global |
TST001 Claudin 18.2 Solid Tumors |
![]() ![]() TST001 - Claudin 18.2 - Solid Tumors
Territory:Global |
Global |
MSB0254 VEGFR2 Solid Tumors |
MSB0254 - VEGFR2 - Solid Tumors
Territory:Global |
Global |
JCT205 DR5 Solid Tumors |
![]() ![]() JCT205 - DR5 - Solid Tumors
Territory:Greater China(In-licensed from InhibRx) |
Greater China(In-licensed from InhibRx) |
TST005 PDL1-TGFβ Bispecific Solid Tumors |
TST005 - PDL1-TGFβ Bispecific - Solid Tumors
Territory:Global |
Global |
TST002 Sclerostin Osteoporosis |
![]() ![]() TST002 - Sclerostin - Osteoporosis
Territory:Greater China
(In-licensed from |
Greater China
(In-licensed from |
TST003 Undisclosed Solid Tumors |
TST003 - Undisclosed - Solid Tumors
Territory:Global |
Global |
TST004 MASP2 Nephrology |
TST004 - MASP2 - Nephrology
Territory:Global |
Global |
TST006 Undisclosed Oncology |
TST006 - Undisclosed - Oncology
Territory:Global |
Global |
TST007 Undisclosed Oncology |
TST007 - Undisclosed - Oncology
Territory:Global |
Global |
TST008 Undisclosed Nephrology |
TST008 - Undisclosed - Nephrology
Territory:Global |
Global |
Non-oncology
Oncology
Program:
MSB2311Target:
PD-L1Indication:
Solid TumorsAlbert has 15 years of experience in the financial field and has worked in the Audit and Trading Consulting department of PWC, providing IPO audits, annual audits, transaction due diligence, post management, transaction integration and other related financial advisory services. Over the past 10 years, he has been responsible for assisting clients to list in mainland China and Hong Kong's capital markets by verifying compliance with the rules of relevant capital market regulation and reporting.